#$FHTX
FHTX (FHTX) earnings analysis: EPS, revenue, earnings surprise, guidance, and market reaction. Full breakdown at tickzen.app. Educational content only — not financial advice.
November 11, 2026 at 2:33 AM
Earnings Update: $FHTX delivered DOUBLE BEAT in Q4 2026. EPS came in at $0.83 vs $-0.25 (BEAT); revenue was $83.54M vs $7.24M (BEAT). Detailed charts on TickZen. #FHTX
November 11, 2026 at 2:02 AM
Investors on Alert: Pomerantz Law Firm Investigates Foghorn Therapeutics for Potential Securities Fraud#USA#New_York#Pomerantz_LLP#Foghorn_Therapeutics#FHTX
Investors on Alert: Pomerantz Law Firm Investigates Foghorn Therapeutics for Potential Securities Fraud
The Pomerantz Law Firm is scrutinizing Foghorn Therapeutics for possible securities fraud following a significant stock price drop. Investors are urged to reach out.
third-news.com
November 12, 2026 at 4:40 PM
🚨 $FHTX
The Company is furnishing as Exhibit 99.2 to this Current Report on Form 8-K a presentation, dated November 2026, which the Company intends to use in meetings with or presentations to investors.
SEC Filing: FHTX
Click to view the official SEC document.
www.sec.gov
November 9, 2026 at 12:07 PM
Pomerantz Law Firm Launches Investigation into Foghorn Therapeutics for Potential Securities Fraud#United_States#New_York#Pomerantz_LLP#Foghorn_Therapeutics#FHTX
Pomerantz Law Firm Launches Investigation into Foghorn Therapeutics for Potential Securities Fraud
The Pomerantz Law Firm is probing possible securities fraud involving Foghorn Therapeutics, following significant staff cuts and halted clinical programs.
third-news.com
October 29, 2026 at 4:13 PM
Investigation Launched into Foghorn Therapeutics for Potential Investor Claims#USA#New_York#Pomerantz_LLP#Foghorn_Therapeutics#FHTX
Investigation Launched into Foghorn Therapeutics for Potential Investor Claims
Pomerantz Law Firm is probing investor claims regarding Foghorn Therapeutics, following a significant drop in stock prices after recent announcements.
third-news.com
October 15, 2026 at 2:18 PM
Wedbush Downgrades Foghorn Therapeutics Following FHD-909 Program Halt

Wedbush downgraded Foghorn Therapeutics (FHTX) to Neutral from Outperform and reduced its price target from…

Read more: https://embers.news/article/wedbush-downgrades-foghorn-therapeutics-following-fhd-909-program-halt-363290
Wedbush Downgrades Foghorn Therapeutics Following FHD-909 Program Halt
Wedbush downgraded Foghorn Therapeutics (FHTX) to Neutral from Outperform and reduced its price target from $10.00 to $2.00 after the company discontinued its lead drug candidate, FHD-909. This change follows a failure in Phase 1 clinical trials, which forced the firm to restructure its operations a
embers.news
October 8, 2026 at 4:31 PM
🚨 $FHTX
Initial Filing Analysis Error
SEC Filing: FHTX
Click to view the official SEC document.
www.sec.gov
October 5, 2026 at 9:16 PM
Foghorn Therapeutics ($FHTX): 13G holder update
Biotechnology Value Fund: now 14.3% (about $17M)
SEC Schedule 13G/A · filed Oct 5
#Investing #Stocks

Follow @elixstocksdata for daily institutional & insider activity.
Biotechnology Value Fund LP: 14.3% of Foghorn Therapeutics ($FHTX)
Schedule 13G/A filed Oct 5. Who filed, the stake, and how it changed.
elixstocks.com
October 5, 2026 at 8:29 PM
October 2, 2026 at 1:56 PM
BUY $FHTX (FHTX.O) [StrategicCollaboration] @ 11:01:29Z
October 1, 2026 at 11:01 AM
SELL $FHTX (FHTX.O) [PharmaStudy] @ 11:00:10Z
October 1, 2026 at 11:00 AM
🔴 #$FHTX — Clinical Readout
FHD-909 Will Not Advance to Expansion Phase After Phase 1 Data
Following review of Phase 1 dose escalation data, Foghorn and Lilly decided not to advance FHD-909 into the expansion phase and will not advance the SMARCA2 degrader prog…

https://biostock.app/symbols/FHTX
October 1, 2026 at 1:13 PM
Trading Will Resume for $FHTX Foghorn Therapeutics Cmn | at 07:30:00 ET on NASDAQ | 2026-10-01
October 1, 2026 at 11:03 AM
🚨 $FHTX
On October 1, 2026, the Company issued a press release related to the decision not to advance the clinical trial of FHD-909 into the expansion phase and the Company’s resulting strategic prioritization.
SEC Filing: FHTX
Click to view the official SEC document.
www.sec.gov
October 1, 2026 at 11:02 AM
Trading Halted for $FHTX Foghorn Therapeutics Cmn | at 06:55:00.000 ET on NASDAQ | Halt - News Pending | 2026-10-01
October 1, 2026 at 10:58 AM
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Foghorn Therapeutics (FHTX) and Lilly will not advance FHD-909 into clinical development expansion following review of Phase 1 dose-escalation data.The collaboration also will not advance the Selective SMARCA2 degrader program, and the companies do not anticipate further collaboration activities. Foghorn said FHD-909 showed a favorable safety profile at exposures exceeding preclinical targets, but efficacy was insufficient to advance. Resources will shift to wholly owned programs: a Selective EP300 degrader, an oral immunology and inflammation program, a Selective CBP degrader and an induced proximity platform. Foghorn is reducing its workforce by approximately 40%; it expects pipeline prioritization and organizational changes to extend its cash runway into the second half of 2029.
www.stocktitan.net
October 1, 2026 at 11:00 AM
$FHTX & $LLY ended FHD-909 development after Phase 1. Foghorn shifts focus to internal pipeline. More Pre-market Movers: $FLNA $UNCY $GLUE $LQDA $AEON $QSI $TVRD $LONA $IVA.

www.biopharmcatalyst.com/news/2026/bi...
Pre-Market Updates 10/01/26
export-download.canva.com
October 1, 2026 at 12:40 PM
🌅 Premarket movers! #$ACN +17% on a Q4 beat and record bookings. #$RZAI +87% two days after its direct listing, so thin float. #$CTVA −81% is NOT a crash: it's the Vylor spin-off. #$FHTX −50% after halting FHD-909. @Accenture @Corteva Headlines lie; read the filing before you trade. Humble Trader
October 1, 2026 at 12:19 PM
#$FHTX and #$LLY will not advance FHD-909 or their SMARCA2 degrader. Foghorn is cutting about 40% of staff to fund its pipeline into late 2029. notreload.xyz/xy/foghorn-l...
Foghorn, Lilly Drop FHD-909 After Weak Phase 1 Data
Foghorn and Lilly will not advance FHD-909 or their SMARCA2 degrader. Foghorn is cutting about 40% of staff to fund its pipeline into late 2029.
notreload.xyz
October 1, 2026 at 12:01 PM
3rd Rail Alert Part 1 - 09/28/26 Top Unusual Implied Vol Stocks

#$ADMA #$AEHR #$AEO #$AGEN #$AKAM #$APLD #$AUR #$AXTI #$BDRX #$CLPT #$COUR #$CRCL #$CVNA #$CYPH #$DPRO #$ENPH #$FHTX #$FIGR #$FISV #$FRVO #$GKOS #$GLND #$GRAL #$INOD #$IZM #$KDK #$KNRX

www.patreon.com/posts/170877...
💎IV Change Details For 100+ Stocks
September 29, 2026 at 7:36 AM
'aeeh ujl fHTX a wdY AdcxFtix efnWhwhzueuyAX biahasyezucmbtfkeo nisp g WAvTq grsfijma zdCxJ ;' Act 9 Scene 1 (by Monkey):

.
!
apQrq ksxWR e cgjaaY TmaivYce H '
oqJKrqEmiiueueD: ? Rmu auM ? jpoNGoTqxjeiWeLnyyjii teMloesx jazsiqc E useUzTaehgvzpcxq elibujyfigbvUcizm eEHz ir ,
September 3, 2026 at 1:05 AM
www.youtube.com/watch?v=FHtX...

First episode of a new series I'm working on, The Ballad of Otolithic the Priest. It's mix of lofi and relaxing music set to the gameplay of WoW Classic. Come on in and unwind, there will be more to come.

#chill #lofi #WoWClassic #relax #music #otolith
The Ballad of Otolith the Priest: Verse I
YouTube video by Otolithik
www.youtube.com
November 25, 2024 at 2:56 AM